RELMADA THERAPEUTICS, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent
RELMADA THERAPEUTICS, INC. (RLMD) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent of -2.58% for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-19.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense · last filed 2026-03-19
- RELMADA THERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2024 was -2.58%.
- RELMADA THERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2023 was -5.34%.
- RELMADA THERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2022 was -0.53%.
- RELMADA THERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2021 was -0.38%, a 190.48% decline from fiscal 2020.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 6 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 12 month |
|---|---|---|
| 2024-12-31 | -2.58% 10-K · filed 2026-03-19 | |
| 2023-12-31 | -5.34% 10-K · filed 2025-03-27 | |
| 2022-12-31 | -0.53% 10-K · filed 2024-03-19 | |
| 2021-12-31 | -0.38% 10-K · filed 2023-03-23 | |
| 2020-12-31 | 0.42% 10-K · filed 2022-03-25 | |
| 2019-12-31 | -5.75% 10-K · filed 2021-03-24 | -4.24% 10-K · filed 2021-03-24 |
| 2019-06-30 | -6.30% 10-K · filed 2021-03-24 | |
| 2018-12-31 | -8.50% 10-KT · filed 2020-03-26 | |
| 2018-06-30 | -6.00% 10-KT · filed 2020-03-26 | |
| 2017-06-30 | -0.75% 10-K · filed 2018-09-28 | |
| 2016-06-30 | 25.00% 10-K · filed 2017-09-28 | |
| 2015-06-30 | -9.70% 10-K · filed 2016-09-09 | |
| 2014-12-31 | -13.10% 10-K · filed 2015-09-11 | |
| 2014-06-30 | -13.10% 10-KT · filed 2014-09-09 | |
| 2013-12-31 | -29.70% 10-K · filed 2015-09-11 | |
| 2012-12-31 | -18.80% 10-KT · filed 2014-09-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |